Skip to main content

Table 1 Participant demographics

From: Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin

Measure

ASD (n = 13)

Neurotypicals (n = 15)

Test statistic

Age at visit 1 (years)

30.6 ± 11.2 [20–50]

28.5 ± 6.1 [21–40]

F(1, 26) = 0.389, p = .538

ADI coma

7.5 ± 5.0

  

ADI repa

4.0 ± 2.6

  

ADOS com

4.4 ± 3.3

  

ADOS soc

7.6 ± 4.1

  

AQa

29.1 ± 13.7

  

FSIQ

113.0 ± 18.1

125.3 ± 12.7

F(1, 26) = 4.421, p = .045

TV1–V2 (days)

31.2 ± 17.9

28.1 ± 15.0

F(1, 26) = 0.248, p = .623

Mean motion (CBDV)

0.015 ± 0.067

0.008 ± 0.043

F(1, 26) = 0.100, p = .754

Mean motion (PLC)

0.014 ± 0.049

0.008 ± 0.050

F(1, 26) = 0.097, p = .758

  1. Demographics (mean ± standard deviation [range])) and test statistic of between-group comparison
  2. ADI autism diagnostic interview (com, communication domain; rep, restricted and repetitive behaviours domain), ADOS autism diagnostic observation schedule (com, communication domain; soc, social domain), AQ autism quotient, CBDV cannabidivarin, FSIQ full-scale intelligence quotient, PLC placebo, TV1V2, time between visits 1 and 2
  3. an = 10